ID   GLGB_HUMAN              Reviewed;         702 AA.
AC   Q04446; B3KWV3; Q96EN0;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   16-NOV-2011, sequence version 3.
DT   10-MAY-2017, entry version 173.
DE   RecName: Full=1,4-alpha-glucan-branching enzyme;
DE            EC=2.4.1.18 {ECO:0000269|PubMed:26199317, ECO:0000269|PubMed:8613547, ECO:0000305|PubMed:8463281};
DE   AltName: Full=Brancher enzyme;
DE   AltName: Full=Glycogen-branching enzyme;
GN   Name=GBE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND
RP   VARIANT VAL-334.
RC   TISSUE=Liver;
RX   PubMed=8463281;
RA   Thon V.J., Khalil M., Cannon J.F.;
RT   "Isolation of human glycogen branching enzyme cDNAs by screening
RT   complementation in yeast.";
RL   J. Biol. Chem. 268:7509-7513(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-265 AND
RP   VAL-334.
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-173, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) IN COMPLEXES WITH MALTOHEPTAOSE
RP   AND ACARBOSE, CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, PATHWAY,
RP   CHARACTERIZATION OF VARIANT GSDA SER-329, AND DOMAIN.
RX   PubMed=26199317; DOI=10.1093/hmg/ddv280;
RA   Froese D.S., Michaeli A., McCorvie T.J., Krojer T., Sasi M.,
RA   Melaev E., Goldblum A., Zatsepin M., Lossos A., Alvarez R.,
RA   Escriba P.V., Minassian B.A., von Delft F., Kakhlon O., Yue W.W.;
RT   "Structural basis of glycogen branching enzyme deficiency and
RT   pharmacologic rescue by rational peptide design.";
RL   Hum. Mol. Genet. 24:5667-5676(2015).
RN   [10]
RP   VARIANTS GSD4 PRO-224; LEU-257; SER-329 AND CYS-515, CHARACTERIZATION
RP   OF VARIANTS GSD4 PRO-224; LEU-257; SER-329 AND CYS-515, FUNCTION,
RP   PATHWAY, AND CATALYTIC ACTIVITY.
RX   PubMed=8613547; DOI=10.1172/JCI118517;
RA   Bao Y., Kishnani P., Wu J.Y., Chen Y.T.;
RT   "Hepatic and neuromuscular forms of glycogen storage disease type IV
RT   caused by mutations in the same glycogen-branching enzyme gene.";
RL   J. Clin. Invest. 97:941-948(1996).
RN   [11]
RP   VARIANT GSD4 GLN-524.
RX   PubMed=10545044; DOI=10.1016/S0960-8966(99)00040-1;
RA   Bruno C., DiRocco M., Lamba L.D., Bado M., Marino C., Tsujino S.,
RA   Shanske S., Stella G., Minetti C., van Diggelen O.P., DiMauro S.;
RT   "A novel missense mutation in the glycogen branching enzyme gene in a
RT   child with myopathy and hepatopathy.";
RL   Neuromuscul. Disord. 9:403-407(1999).
RN   [12]
RP   VARIANTS APBN HIS-515 AND GLN-524.
RX   PubMed=10762170;
RX   DOI=10.1002/1531-8249(200004)47:4<536::AID-ANA22>3.3.CO;2-B;
RA   Ziemssen F., Sindern E., Schroder J.M., Shin Y.S., Zange J.,
RA   Kilimann M.W., Malin J.P., Vorgerd M.;
RT   "Novel missense mutations in the glycogen-branching enzyme gene in
RT   adult polyglucosan body disease.";
RL   Ann. Neurol. 47:536-540(2000).
RN   [13]
RP   INVOLVEMENT IN NEUROMUSCULAR PERINATAL GSD4, AND VARIANTS GSD4
RP   GLN-524; ARG-545 AND ARG-628.
RX   PubMed=15452297; DOI=10.1212/01.WNL.0000138429.11433.0D;
RA   Bruno C., van Diggelen O.P., Cassandrini D., Gimpelev M., Giuffre B.,
RA   Donati M.A., Introvini P., Alegria A., Assereto S., Morandi L.,
RA   Mora M., Tonoli E., Mascelli S., Traverso M., Pasquini E., Bado M.,
RA   Vilarinho L., van Noort G., Mosca F., DiMauro S., Zara F., Minetti C.;
RT   "Clinical and genetic heterogeneity of branching enzyme deficiency
RT   (glycogenosis type IV).";
RL   Neurology 63:1053-1058(2004).
CC   -!- FUNCTION: Required for normal glycogen accumulation
CC       (PubMed:8463281, PubMed:26199317, PubMed:8613547). The alpha 1-6
CC       branches of glycogen play an important role in increasing the
CC       solubility of the molecule (Probable).
CC       {ECO:0000269|PubMed:26199317, ECO:0000269|PubMed:8463281,
CC       ECO:0000269|PubMed:8613547, ECO:0000305}.
CC   -!- CATALYTIC ACTIVITY: Transfers a segment of a (1->4)-alpha-D-glucan
CC       chain to a primary hydroxy group in a similar glucan chain.
CC       {ECO:0000269|PubMed:26199317, ECO:0000269|PubMed:8613547,
CC       ECO:0000305|PubMed:8463281}.
CC   -!- PATHWAY: Glycan biosynthesis; glycogen biosynthesis.
CC       {ECO:0000269|PubMed:26199317, ECO:0000269|PubMed:8463281,
CC       ECO:0000269|PubMed:8613547}.
CC   -!- SUBUNIT: Monomer. {ECO:0000305|PubMed:26199317}.
CC   -!- DOMAIN: Binds its carbohydrate substrate close to the active site,
CC       but also via regions close to the N-terminus; this may result in
CC       increased affinity and therefore increased catalytic efficiency.
CC       {ECO:0000305|PubMed:26199317}.
CC   -!- DISEASE: Glycogen storage disease 4 (GSD4) [MIM:232500]: A
CC       metabolic disorder characterized by the accumulation of an
CC       amylopectin-like polysaccharide. The typical clinical
CC       manifestation is liver disease of childhood, progressing to lethal
CC       hepatic cirrhosis. Most children with this condition die before
CC       two years of age. However, the liver disease is not always
CC       progressive. No treatment apart from liver transplantation has
CC       been found to prevent progression of the disease. There is also a
CC       neuromuscular form of glycogen storage disease type 4 that varies
CC       in onset (perinatal, congenital, juvenile, or adult) and severity.
CC       {ECO:0000269|PubMed:10545044, ECO:0000269|PubMed:15452297,
CC       ECO:0000269|PubMed:8613547}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Neuromuscular perinatal glycogen storage disease
CC       type 4 is associated with non-immune hydrops fetalis, a
CC       generalized edema of the fetus with fluid accumulation in the body
CC       cavities due to non-immune causes. Non-immune hydrops fetalis is
CC       not a diagnosis in itself but a symptom, a feature of many genetic
CC       disorders, and the end-stage of a wide variety of disorders.
CC       {ECO:0000269|PubMed:15452297}.
CC   -!- DISEASE: Polyglucosan body neuropathy, adult form (APBN)
CC       [MIM:263570]: A late-onset, slowly progressive disorder affecting
CC       the central and peripheral nervous systems. Patients typically
CC       present after age 40 years with a variable combination of
CC       cognitive impairment, pyramidal tetraparesis, peripheral
CC       neuropathy, and neurogenic bladder. Other manifestations include
CC       cerebellar dysfunction and extrapyramidal signs. The pathologic
CC       hallmark of APBN is the widespread accumulation of round,
CC       intracellular polyglucosan bodies throughout the nervous system,
CC       which are confined to neuronal and astrocytic processes.
CC       {ECO:0000269|PubMed:10762170}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 13 family. GlgB
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L07956; AAA58642.1; -; mRNA.
DR   EMBL; AK125918; BAG54265.1; -; mRNA.
DR   EMBL; AC017015; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025029; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC099049; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012098; AAH12098.1; -; mRNA.
DR   CCDS; CCDS54612.1; -.
DR   PIR; A46075; A46075.
DR   RefSeq; NP_000149.3; NM_000158.3.
DR   UniGene; Hs.436062; -.
DR   PDB; 4BZY; X-ray; 2.75 A; A/B/C=1-702.
DR   PDB; 5CLT; X-ray; 2.79 A; A/B/C=38-700.
DR   PDB; 5CLW; X-ray; 2.80 A; A/B/C=38-700.
DR   PDBsum; 4BZY; -.
DR   PDBsum; 5CLT; -.
DR   PDBsum; 5CLW; -.
DR   ProteinModelPortal; Q04446; -.
DR   SMR; Q04446; -.
DR   BioGrid; 108902; 29.
DR   IntAct; Q04446; 12.
DR   MINT; MINT-1415803; -.
DR   STRING; 9606.ENSP00000410833; -.
DR   CAZy; CBM48; Carbohydrate-Binding Module Family 48.
DR   CAZy; GH13; Glycoside Hydrolase Family 13.
DR   iPTMnet; Q04446; -.
DR   PhosphoSitePlus; Q04446; -.
DR   SwissPalm; Q04446; -.
DR   BioMuta; GBE1; -.
DR   DMDM; 357529509; -.
DR   EPD; Q04446; -.
DR   MaxQB; Q04446; -.
DR   PaxDb; Q04446; -.
DR   PeptideAtlas; Q04446; -.
DR   PRIDE; Q04446; -.
DR   DNASU; 2632; -.
DR   Ensembl; ENST00000429644; ENSP00000410833; ENSG00000114480.
DR   GeneID; 2632; -.
DR   KEGG; hsa:2632; -.
DR   UCSC; uc062lqz.1; human.
DR   CTD; 2632; -.
DR   DisGeNET; 2632; -.
DR   GeneCards; GBE1; -.
DR   GeneReviews; GBE1; -.
DR   HGNC; HGNC:4180; GBE1.
DR   HPA; HPA038073; -.
DR   HPA; HPA038074; -.
DR   HPA; HPA038075; -.
DR   MalaCards; GBE1; -.
DR   MIM; 232500; phenotype.
DR   MIM; 263570; phenotype.
DR   MIM; 607839; gene.
DR   neXtProt; NX_Q04446; -.
DR   OpenTargets; ENSG00000114480; -.
DR   Orphanet; 206583; Adult polyglucosan body disease.
DR   Orphanet; 308712; Glycogen storage disease due to glycogen branching enzyme deficiency, adult neuromuscular form.
DR   Orphanet; 308684; Glycogen storage disease due to glycogen branching enzyme deficiency, childhood combined hepatic and myopathic form.
DR   Orphanet; 308698; Glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form.
DR   Orphanet; 308670; Glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form.
DR   Orphanet; 308655; Glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form.
DR   Orphanet; 308638; Glycogen storage disease due to glycogen branching enzyme deficiency, non progressive hepatic form.
DR   Orphanet; 308621; Glycogen storage disease due to glycogen branching enzyme deficiency, progressive hepatic form.
DR   PharmGKB; PA28594; -.
DR   eggNOG; KOG0470; Eukaryota.
DR   eggNOG; COG0296; LUCA.
DR   GeneTree; ENSGT00390000017040; -.
DR   HOVERGEN; HBG051734; -.
DR   InParanoid; Q04446; -.
DR   KO; K00700; -.
DR   OMA; ICYLTLA; -.
DR   OrthoDB; EOG091G02KX; -.
DR   TreeFam; TF300783; -.
DR   BioCyc; MetaCyc:HS03772-MONOMER; -.
DR   Reactome; R-HSA-3322077; Glycogen synthesis.
DR   UniPathway; UPA00164; -.
DR   ChiTaRS; GBE1; human.
DR   GeneWiki; GBE1; -.
DR   GenomeRNAi; 2632; -.
DR   PRO; PR:Q04446; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000114480; -.
DR   CleanEx; HS_GBE1; -.
DR   ExpressionAtlas; Q04446; baseline and differential.
DR   Genevisible; Q04446; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0003844; F:1,4-alpha-glucan branching enzyme activity; IDA:UniProtKB.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:Ensembl.
DR   GO; GO:0043169; F:cation binding; IEA:InterPro.
DR   GO; GO:0004553; F:hydrolase activity, hydrolyzing O-glycosyl compounds; IEA:InterPro.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0005977; P:glycogen metabolic process; TAS:ProtInc.
DR   Gene3D; 2.60.40.10; -; 1.
DR   InterPro; IPR006048; A-amylase/branching_C.
DR   InterPro; IPR006407; GlgB.
DR   InterPro; IPR006047; Glyco_hydro_13_cat_dom.
DR   InterPro; IPR004193; Glyco_hydro_13_N.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   Pfam; PF00128; Alpha-amylase; 1.
DR   Pfam; PF02806; Alpha-amylase_C; 1.
DR   Pfam; PF02922; CBM_48; 1.
DR   PIRSF; PIRSF000463; GlgB; 1.
DR   SMART; SM00642; Aamy; 1.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   SUPFAM; SSF81296; SSF81296; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Disease mutation;
KW   Glycogen biosynthesis; Glycogen storage disease; Glycosyltransferase;
KW   Neuropathy; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22223895}.
FT   CHAIN         2    702       1,4-alpha-glucan-branching enzyme.
FT                                /FTId=PRO_0000188775.
FT   REGION       62     63       Substrate binding. {ECO:0000244|PDB:5CLT,
FT                                ECO:0000244|PDB:5CLW,
FT                                ECO:0000305|PubMed:26199317}.
FT   REGION       91     93       Substrate binding. {ECO:0000244|PDB:5CLT,
FT                                ECO:0000244|PDB:5CLW,
FT                                ECO:0000305|PubMed:26199317}.
FT   REGION      118    121       Substrate binding. {ECO:0000244|PDB:5CLT,
FT                                ECO:0000244|PDB:5CLW,
FT                                ECO:0000305|PubMed:26199317}.
FT   REGION      333    336       Substrate binding. {ECO:0000244|PDB:5CLT,
FT                                ECO:0000244|PDB:5CLW,
FT                                ECO:0000305|PubMed:26199317}.
FT   ACT_SITE    357    357       Nucleophile. {ECO:0000250}.
FT   ACT_SITE    412    412       Proton donor. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22223895}.
FT   MOD_RES     173    173       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   VARIANT     190    190       R -> G (in dbSNP:rs2229519).
FT                                /FTId=VAR_022109.
FT   VARIANT     224    224       L -> P (in GSD4; loss of activity;
FT                                dbSNP:rs137852886).
FT                                {ECO:0000269|PubMed:8613547}.
FT                                /FTId=VAR_022429.
FT   VARIANT     257    257       F -> L (in GSD4; loss of activity;
FT                                dbSNP:rs137852887).
FT                                {ECO:0000269|PubMed:8613547}.
FT                                /FTId=VAR_022430.
FT   VARIANT     265    265       T -> S (in dbSNP:rs17856389).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_034747.
FT   VARIANT     329    329       Y -> S (in GSD4; non-progressive form;
FT                                impairs protein stability; 50% residual
FT                                activity; dbSNP:rs80338671).
FT                                {ECO:0000269|PubMed:26199317,
FT                                ECO:0000269|PubMed:8613547}.
FT                                /FTId=VAR_022431.
FT   VARIANT     334    334       I -> V (in dbSNP:rs2172397).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8463281}.
FT                                /FTId=VAR_034748.
FT   VARIANT     507    507       T -> A (in dbSNP:rs2228389).
FT                                /FTId=VAR_034749.
FT   VARIANT     515    515       R -> C (in GSD4; loss of activity;
FT                                dbSNP:rs80338672).
FT                                {ECO:0000269|PubMed:8613547}.
FT                                /FTId=VAR_022432.
FT   VARIANT     515    515       R -> H (in APBN; dbSNP:rs201958741).
FT                                {ECO:0000269|PubMed:10762170}.
FT                                /FTId=VAR_022433.
FT   VARIANT     524    524       R -> Q (in GSD4 and APBN;
FT                                dbSNP:rs80338673).
FT                                {ECO:0000269|PubMed:10545044,
FT                                ECO:0000269|PubMed:10762170,
FT                                ECO:0000269|PubMed:15452297}.
FT                                /FTId=VAR_022434.
FT   VARIANT     545    545       H -> R (in GSD4; dbSNP:rs137852889).
FT                                {ECO:0000269|PubMed:15452297}.
FT                                /FTId=VAR_022435.
FT   VARIANT     628    628       H -> R (in GSD4; childhood neuromuscular
FT                                form; 15 to 25% residual activity;
FT                                dbSNP:rs137852891).
FT                                {ECO:0000269|PubMed:15452297}.
FT                                /FTId=VAR_022436.
FT   CONFLICT     88     88       C -> S (in Ref. 1; AAA58642).
FT                                {ECO:0000305}.
FT   HELIX        45     62       {ECO:0000244|PDB:4BZY}.
FT   STRAND       63     65       {ECO:0000244|PDB:5CLW}.
FT   HELIX        66     69       {ECO:0000244|PDB:4BZY}.
FT   HELIX        70     74       {ECO:0000244|PDB:4BZY}.
FT   STRAND       76     80       {ECO:0000244|PDB:4BZY}.
FT   STRAND       86     91       {ECO:0000244|PDB:4BZY}.
FT   STRAND       96    102       {ECO:0000244|PDB:4BZY}.
FT   HELIX       103    105       {ECO:0000244|PDB:4BZY}.
FT   STRAND      109    113       {ECO:0000244|PDB:4BZY}.
FT   HELIX       118    120       {ECO:0000244|PDB:5CLT}.
FT   STRAND      121    126       {ECO:0000244|PDB:4BZY}.
FT   STRAND      141    147       {ECO:0000244|PDB:4BZY}.
FT   STRAND      153    156       {ECO:0000244|PDB:4BZY}.
FT   STRAND      174    176       {ECO:0000244|PDB:4BZY}.
FT   STRAND      195    204       {ECO:0000244|PDB:4BZY}.
FT   STRAND      207    212       {ECO:0000244|PDB:4BZY}.
FT   HELIX       216    222       {ECO:0000244|PDB:4BZY}.
FT   HELIX       224    230       {ECO:0000244|PDB:4BZY}.
FT   STRAND      234    239       {ECO:0000244|PDB:4BZY}.
FT   STRAND      241    244       {ECO:0000244|PDB:5CLT}.
FT   HELIX       246    248       {ECO:0000244|PDB:4BZY}.
FT   STRAND      254    259       {ECO:0000244|PDB:4BZY}.
FT   HELIX       261    263       {ECO:0000244|PDB:4BZY}.
FT   HELIX       266    278       {ECO:0000244|PDB:4BZY}.
FT   STRAND      282    288       {ECO:0000244|PDB:4BZY}.
FT   STRAND      292    294       {ECO:0000244|PDB:5CLT}.
FT   STRAND      296    300       {ECO:0000244|PDB:4BZY}.
FT   TURN        301    304       {ECO:0000244|PDB:4BZY}.
FT   STRAND      305    307       {ECO:0000244|PDB:4BZY}.
FT   STRAND      309    311       {ECO:0000244|PDB:4BZY}.
FT   HELIX       315    317       {ECO:0000244|PDB:4BZY}.
FT   TURN        320    323       {ECO:0000244|PDB:4BZY}.
FT   HELIX       332    347       {ECO:0000244|PDB:4BZY}.
FT   STRAND      353    357       {ECO:0000244|PDB:4BZY}.
FT   HELIX       359    363       {ECO:0000244|PDB:4BZY}.
FT   TURN        379    382       {ECO:0000244|PDB:5CLT}.
FT   HELIX       387    403       {ECO:0000244|PDB:4BZY}.
FT   STRAND      408    411       {ECO:0000244|PDB:4BZY}.
FT   TURN        418    421       {ECO:0000244|PDB:4BZY}.
FT   HELIX       424    426       {ECO:0000244|PDB:4BZY}.
FT   STRAND      432    435       {ECO:0000244|PDB:4BZY}.
FT   HELIX       438    449       {ECO:0000244|PDB:4BZY}.
FT   HELIX       452    454       {ECO:0000244|PDB:4BZY}.
FT   HELIX       457    465       {ECO:0000244|PDB:4BZY}.
FT   STRAND      473    475       {ECO:0000244|PDB:4BZY}.
FT   HELIX       481    483       {ECO:0000244|PDB:4BZY}.
FT   HELIX       490    495       {ECO:0000244|PDB:4BZY}.
FT   HELIX       496    500       {ECO:0000244|PDB:4BZY}.
FT   HELIX       511    530       {ECO:0000244|PDB:4BZY}.
FT   STRAND      533    538       {ECO:0000244|PDB:4BZY}.
FT   HELIX       541    543       {ECO:0000244|PDB:4BZY}.
FT   HELIX       554    556       {ECO:0000244|PDB:4BZY}.
FT   STRAND      561    564       {ECO:0000244|PDB:5CLW}.
FT   HELIX       567    570       {ECO:0000244|PDB:4BZY}.
FT   HELIX       577    594       {ECO:0000244|PDB:4BZY}.
FT   STRAND      597    599       {ECO:0000244|PDB:4BZY}.
FT   STRAND      603    608       {ECO:0000244|PDB:4BZY}.
FT   TURN        609    612       {ECO:0000244|PDB:4BZY}.
FT   STRAND      613    618       {ECO:0000244|PDB:4BZY}.
FT   STRAND      621    626       {ECO:0000244|PDB:4BZY}.
FT   STRAND      633    642       {ECO:0000244|PDB:4BZY}.
FT   STRAND      644    651       {ECO:0000244|PDB:4BZY}.
FT   HELIX       655    657       {ECO:0000244|PDB:4BZY}.
FT   STRAND      669    673       {ECO:0000244|PDB:4BZY}.
FT   STRAND      679    687       {ECO:0000244|PDB:4BZY}.
FT   STRAND      691    698       {ECO:0000244|PDB:4BZY}.
SQ   SEQUENCE   702 AA;  80474 MW;  DEF534C821A72323 CRC64;
     MAAPMTPAAR PEDYEAALNA ALADVPELAR LLEIDPYLKP YAVDFQRRYK QFSQILKNIG
     ENEGGIDKFS RGYESFGVHR CADGGLYCKE WAPGAEGVFL TGDFNGWNPF SYPYKKLDYG
     KWELYIPPKQ NKSVLVPHGS KLKVVITSKS GEILYRISPW AKYVVREGDN VNYDWIHWDP
     EHSYEFKHSR PKKPRSLRIY ESHVGISSHE GKVASYKHFT CNVLPRIKGL GYNCIQLMAI
     MEHAYYASFG YQITSFFAAS SRYGTPEELQ ELVDTAHSMG IIVLLDVVHS HASKNSADGL
     NMFDGTDSCY FHSGPRGTHD LWDSRLFAYS SWEILRFLLS NIRWWLEEYR FDGFRFDGVT
     SMLYHHHGVG QGFSGDYSEY FGLQVDEDAL TYLMLANHLV HTLCPDSITI AEDVSGMPAL
     CSPISQGGGG FDYRLAMAIP DKWIQLLKEF KDEDWNMGDI VYTLTNRRYL EKCIAYAESH
     DQALVGDKSL AFWLMDAEMY TNMSVLTPFT PVIDRGIQLH KMIRLITHGL GGEGYLNFMG
     NEFGHPEWLD FPRKGNNESY HYARRQFHLT DDDLLRYKFL NNFDRDMNRL EERYGWLAAP
     QAYVSEKHEG NKIIAFERAG LLFIFNFHPS KSYTDYRVGT ALPGKFKIVL DSDAAEYGGH
     QRLDHSTDFF SEAFEHNGRP YSLLVYIPSR VALILQNVDL PN
//
